The invention is related to a dengue virus or chimeric dengue virus that contains a mutation in the 3 untranslated region (3-UTR) comprising a 30 mutation that removes the TL-2 homologous structure in each of the dengue virus serotypes 1, 2, 3, and 4, and nucleotides additional to the 30 mutation deleted from the 3-UTR that removes sequence in the 5 direction as far as the 5 boundary of the TL-3 homologous structure in each of the dengue serotypes 1, 2, 3, and 4, or a replacement of the 3-UTR of a dengue virus of a first serotype with the 3-UTR of a dengue virus of a second serotype, optionally containing the 30 mutation and nucleotides additional to the 30 mutation deleted from the 3-UTR; and immunogenic compositions, methods of inducing an immune response, and methods of producing a dengue virus or chimeric dengue virus.

A method for preparing serotype O foot-and-mouth disease virus-like particles, the method including: construction of small ubiquitin-like modifier fusion expression vector, construction of recombinant expression vectors, construction of recombinant co-expression vector, expression and purification of proteins, and in-vitro assembly of serotype O foot-and-mouth disease virus-like particles. The disclosure also provides a test strip for detecting serotype O foot-and-mouth disease including a bottom board, and a detection layer disposed on the top of the bottom board. A detection line and a control line are disposed on the detection layer. An absorbent layer is disposed at one end of the detection layer close to the control line, and an immuno-gold pad is disposed at the other side of the detection layer close to the detection line. A sample pad is disposed on the top of the immuno-gold pad.

The present invention is directed to improved methods of Enterovirus inactivation by formaldehyde in presence of tromethamine buffer resulting in maximum recovery of D-antigen. Subsequent adsorption of said sIPV on aluminium hydroxide provides significantly dose reduced sIPV compositions.

Described herein are mutant pneumoviruses comprising a nucleotide sequence which encodes a mutated zinc binding motif in an M2-1 protein of the pneumovirus, wherein the zinc binding motif is mutated relative to wild-type pneumovirus. The mutant pneumoviruses described herein grow to high titer in cell culture, are genetically stable, are attenuated in vitro and in vivo, and are highly immunogenic. Also described herein are vaccines and vaccine compositions comprising the live attenuated mutant pneumoviruses. Vaccine compositions can further comprise a pharmaceutically acceptable carrier, vehicle, excipient, and/or adjuvant. Methods for inducing a protective immune response in a subject against a pneumovirus infection are also described and disclosed. The vaccine compositions and methods described herein can be used to prevent metapneumovirus and respiratory syncytial virus infection in humans, respiratory syncytial virus infection in cattle, avian metapneumovirus infection in various avian species, and pneumonia virus of mice in rodents.

The compositions and methods are described for generating an immune response to a tumor associated antigen such as MUC1. The compositions and methods described herein relate to a modified vaccinia Ankara (MVA) vector encoding one or more viral antigens for generating a protective immune response to a neoplasm expressing the tumor associated antigen in the subject to which the vector is administered. The compositions and methods of the present invention are useful both prophylactically and therapeutically and may be used to prevent and/or treat neoplasms and associated diseases.

The invention features compositions and methods for the prevention or treatment of one or more strains of Chikungunya virus, as well as other alphavirus-mediated diseases.

The invention features compositions and methods for the prevention or treatment of one or more strains of Chikungunya virus, as well as other alphavirus-mediated diseases.

The invention relates to the production of phage and transduction particles using DNAs (eg, plasmids and helper phage, mobile genetic elements (MGEs) or plasmids with chromosomally integrated helper phage genes), as well as the phage, helper phage, kits, compositions and methods involving these.

The invention is related to a dengue virus or chimeric dengue virus that contains a mutation in the 3 untranslated region (3-UTR) comprising a ?30 mutation that removes the TL-2 homologous structure in each of the dengue virus serotypes 1, 2, 3, and 4, and nucleotides additional to the ?30 mutation deleted from the 3-UTR that removes sequence in the 5 direction as far as the 5 boundary of the TL-3 homologous structure in each of the dengue serotypes 1, 2, 3, and 4, or a replacement of the 3-UTR of a dengue virus of a first serotype with the 3-UTR of a dengue virus of a second serotype, optionally containing the ?30 mutation and nucleotides additional to the ?30 mutation deleted from the 3-UTR; and immunogenic compositions, methods of inducing an immune response, and methods of producing a dengue virus or chimeric dengue virus.

The present disclosure provides compositions including recombinant K or 812 bacteriophages, methods for making the same, and uses thereof. The recombinant K or 812 bacteriophages disclosed herein are useful for the identification and/or antibiotic susceptibility profiling of specific bacterial strains/species present in a sample.